What are the major opportunities in the Prostate Cancer Nuclear Medicine Diagnostics market? What are the strategies for the Prostate Cancer Nuclear Medicine Diagnostics market?

For detailed insights on the major opportunities and strategies in the Prostate Cancer Nuclear Medicine Diagnostics market, Read More

How does the Prostate Cancer Nuclear Medicine Diagnostics market relate to the overall economy and other similar markets?

For detailed insights on Prostate Cancer Nuclear Medicine Diagnostics's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Prostate Cancer Nuclear Medicine Diagnostics market growth? SWOT analysis of the Prostate Cancer Nuclear Medicine Diagnostics market.

For detailed insights on the key dynamics influencing the Prostate Cancer Nuclear Medicine Diagnostics market growth and SWOT analysis of the Prostate Cancer Nuclear Medicine Diagnostics industry, Read More

Prostate Cancer Nuclear Medicine Diagnostics Market Global Report 2026 Market Report Infographic Image

Item added to cart!

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

Name: Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Type (Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)), By Test Type (Preliminary Tests, Confirmatory Tests), By End User (Hospitals, Clinics, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Prostate Cancer Nuclear Medicine Diagnostics Market Overview

• Prostate Cancer Nuclear Medicine Diagnostics market size has reached to $0.99 billion in 2025

• Expected to grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 13%

• Growth Driver: Fueling Growth In Prostate Cancer Nuclear Medicine Diagnostics Market

• Market Trend: Targeted Alpha-Particle Radiotherapy Advances Precision Treatment for Prostate Cancer

• North America was the largest region in 2025.

What Is Covered Under Prostate Cancer Nuclear Medicine Diagnostics Market?

Prostate cancer nuclear medicine diagnostics refers to the process of using radioactive substances to detect and evaluate prostate cancer. These diagnostics help in the detection, staging, and management of prostate cancer by providing detailed functional information about the disease's extent and characteristics. Prostate cancer nuclear medicine diagnostics involve the use of radioactive substances (radiopharmaceuticals) that are introduced into the body, typically through injection, and emit gamma rays or positrons.

The main types of prostate cancer nuclear medicine diagnostics are single photon emission computed tomography (SPECT), and photon emission computed tomography (pet). Single photon emission computed tomography (SPECT) is a nuclear imaging technique that generates detailed, three-dimensional images of the body's functional processes. The various test types include preliminary tests and confirmatory tests. These are used by various end-users such as hospitals, clinics, and others.

Prostate Cancer Nuclear Medicine Diagnostics Market Global Report 2026 Market Report bar graph

What Is The Prostate Cancer Nuclear Medicine Diagnostics Market Size and Share 2026?

The prostate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.99 billion in 2025 to $1.13 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to expansion of nuclear medicine infrastructure, increased use of radiotracers in oncology, availability of gamma camera and pet imaging systems, rising prostate cancer diagnosis rates, growth in hospital-based imaging services.

What Is The Prostate Cancer Nuclear Medicine Diagnostics Market Growth Forecast?

The prostate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to advancements in radiopharmaceutical development, rising demand for precise cancer staging tools, expansion of personalized oncology diagnostics, increasing investment in hybrid imaging platforms, growing adoption of molecular imaging techniques. Major trends in the forecast period include increasing adoption of pet and spect imaging modalities, rising use of radiopharmaceutical-based diagnostics, growing demand for functional cancer imaging, expansion of hybrid imaging technologies, enhanced focus on accurate disease staging.

Book your 30 minutes free consultation with our research experts

Global Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

1) By Type: Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)

2) By Test Type: Preliminary Tests, Confirmatory Tests

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT, Hybrid SPECT Or CT Imaging

2) By Positron Emission Tomography (PET): PET Or CT Imaging, PET Or MRI Imaging

What Is The Driver Of The Prostate Cancer Nuclear Medicine Diagnostics Market?

The rise in the prevalence of prostate cancer is expected to propel the growth of the prostate cancer nuclear medicine diagnostics market going forward. Prostate cancer is a type of cancer that occurs in the prostate, a small walnut-shaped gland in males that produces seminal fluid, which nourishes and transports sperm. The rising prevalence of prostate cancer is due to the aging population, lifestyle changes, and genetic factors. Prostate cancer nuclear medicine diagnostics provide valuable insights that enable clinicians to deliver more precise, effective, and personalized care to patients with prostate cancer. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency responsible for international public health, by 2050, over 35 million new cancer cases are projected, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the rise in the prevalence of prostate cancer drives the prostate cancer nuclear medicine diagnostics industry.

Key Players In The Global Prostate Cancer Nuclear Medicine Diagnostics Market

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, Curium Pharma, Telix Pharmaceuticals Ltd, Eckert And Ziegler AG, Point Biopharma Global Inc, Alliance Medical Ltd, SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Isotope Technologies Garching ITG, Jubilant Pharma Limited, Blue Earth Diagnostics Inc, Institute Of Isotopes Co Ltd, Radiopharm Theranostics, Bracco Diagnostic Inc, NCM USA LLC, ABX Advanced Biochemical Compounds GmbH, Theragnostics Ltd, SpectronRx Inc

Global Prostate Cancer Nuclear Medicine Diagnostics Market Trends and Insights

Major companies operating in the prostate cancer nuclear medicine market are focusing on developing advanced solutions such as targeted alpha-particle radiotherapy to enhance treatment precision and minimize off-target effects. Targeted alpha-particle radiotherapy uses radioactive isotopes that emit alpha particles to selectively destroy cancer cells while sparing healthy tissue, providing a highly localized and effective treatment option. For instance, in March 2025, Actinium Pharmaceuticals Inc., a US-based developer of antibody radiation conjugates and other targeted radiotherapies, launched ATNM-400 featuring actinium-225 (Ac-225) radiotherapy. The therapy targets a non-prostate-specific membrane antigen that is overexpressed in prostate cancer patients and provides an alternative for individuals resistant to PSMA-targeted therapies such as Pluvicto. Key features of ATNM-400 include the use of the alpha-particle emitter Ac-225, which can reduce off-target effects compared with beta-particle therapies, and its targeting of a distinct cancer marker to broaden treatment applicability. The launch includes preclinical data demonstrating biodistribution, imaging, and efficacy analyses across various dose levels, with additional results expected from Pluvicto-resistant prostate cancer models. ATNM-400 is positioned to advance precision radiotherapy and improve treatment options for patients with prostate cancer.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Prostate Cancer Nuclear Medicine Diagnostics Market?

In March 2023, Life Healthcare Group, a South Africa-based healthcare company, acquired TheraMed Nuclear for an undisclosed amount. With this acquisition, Life Healthcare enhances its diagnostic imaging services, particularly in detecting and treating diseases like organ dysfunction and cancer. TheraMed Nuclear is a South Africa-based company that offers prostate cancer nuclear medicine diagnostics.

Regional Outlook

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prostate Cancer Nuclear Medicine Diagnostics Market?

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026?

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Prostate Cancer Nuclear Medicine Diagnostics Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$1.13 billion
Revenue Forecast In 2035	$1.84 billion
Growth Rate	CAGR of 14.6% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Type, Test Type, End User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Cardinal Health, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, Curium Pharma, Telix Pharmaceuticals Ltd, Eckert And Ziegler AG, Point Biopharma Global Inc, Alliance Medical Ltd, SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Isotope Technologies Garching ITG, Jubilant Pharma Limited, Blue Earth Diagnostics Inc, Institute Of Isotopes Co Ltd, Radiopharm Theranostics, Bracco Diagnostic Inc, NCM USA LLC, ABX Advanced Biochemical Compounds GmbH, Theragnostics Ltd, SpectronRx Inc
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Prostate Cancer Nuclear Medicine Diagnostics Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Prostate Cancer Nuclear Medicine Diagnostics Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Prostate Cancer Nuclear Medicine Diagnostics Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Pet And Spect Imaging Modalities

4.2.2 Rising Use Of Radiopharmaceutical-Based Diagnostics

4.2.3 Growing Demand For Functional Cancer Imaging

4.2.4 Expansion Of Hybrid Imaging Technologies

4.2.5 Enhanced Focus On Accurate Disease Staging

5. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Diagnostic Imaging Centers

5.3 Oncology Clinics

5.4 Nuclear Medicine Departments

5.5 Academic Research Hospitals

6. Prostate Cancer Nuclear Medicine Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Prostate Cancer Nuclear Medicine Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Prostate Cancer Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, Comparisons And Growth Rate Analysis

7.3. Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Prostate Cancer Nuclear Medicine Diagnostics Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

9.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)

9.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Preliminary Tests, Confirmatory Tests

9.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Clinics, Other End Users

9.4. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Single Photon Emission Computed Tomography (SPECT), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Gamma Camera SPECT, Hybrid SPECT Or CT Imaging

9.5. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Positron Emission Tomography (PET), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

PET Or CT Imaging, PET Or MRI Imaging

10. Prostate Cancer Nuclear Medicine Diagnostics Market Regional And Country Analysis

10.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market

11.1. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Prostate Cancer Nuclear Medicine Diagnostics Market

12.1. China Prostate Cancer Nuclear Medicine Diagnostics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Prostate Cancer Nuclear Medicine Diagnostics Market

13.1. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Prostate Cancer Nuclear Medicine Diagnostics Market

14.1. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Overview

14.2. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Prostate Cancer Nuclear Medicine Diagnostics Market

15.1. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market

16.1. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market

17.1. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Overview

17.2. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Prostate Cancer Nuclear Medicine Diagnostics Market

18.1. Taiwan Prostate Cancer Nuclear Medicine Diagnostics Market Overview

18.2. Taiwan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Prostate Cancer Nuclear Medicine Diagnostics Market

19.1. South East Asia Prostate Cancer Nuclear Medicine Diagnostics Market Overview

19.2. South East Asia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market

20.1. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview

20.2. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Prostate Cancer Nuclear Medicine Diagnostics Market

21.1. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Prostate Cancer Nuclear Medicine Diagnostics Market

22.1. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Prostate Cancer Nuclear Medicine Diagnostics Market

23.1. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Prostate Cancer Nuclear Medicine Diagnostics Market

24.1. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Prostate Cancer Nuclear Medicine Diagnostics Market

25.1. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market

26.1. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview

26.2. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Prostate Cancer Nuclear Medicine Diagnostics Market

27.1. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Prostate Cancer Nuclear Medicine Diagnostics Market

28.1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview

28.2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Prostate Cancer Nuclear Medicine Diagnostics Market

29.1. USA Prostate Cancer Nuclear Medicine Diagnostics Market Overview

29.2. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Prostate Cancer Nuclear Medicine Diagnostics Market

30.1. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Overview

30.2. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Prostate Cancer Nuclear Medicine Diagnostics Market

31.1. South America Prostate Cancer Nuclear Medicine Diagnostics Market Overview

31.2. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market

32.1. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market

33.1. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market Overview

33.2. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Prostate Cancer Nuclear Medicine Diagnostics Market

34.1. Africa Prostate Cancer Nuclear Medicine Diagnostics Market Overview

34.2. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Test Type, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Prostate Cancer Nuclear Medicine Diagnostics Market Regulatory and Investment Landscape

36. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

36.1. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Prostate Cancer Nuclear Medicine Diagnostics Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Prostate Cancer Nuclear Medicine Diagnostics Market Company Profiles

36.3.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

36.3.5. GE Healthcare Overview, Products and Services, Strategy and Financial Analysis

37. Prostate Cancer Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

Lantheus, Curium Pharma, Telix Pharmaceuticals Ltd, Eckert And Ziegler AG, Point Biopharma Global Inc, Alliance Medical Ltd, SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Isotope Technologies Garching ITG, Jubilant Pharma Limited, Blue Earth Diagnostics Inc, Institute Of Isotopes Co Ltd, Radiopharm Theranostics, Bracco Diagnostic Inc

38. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Prostate Cancer Nuclear Medicine Diagnostics Market

40. Prostate Cancer Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

40.1 Prostate Cancer Nuclear Medicine Diagnostics Market In 2030 - Countries Offering Most New Opportunities

40.2 Prostate Cancer Nuclear Medicine Diagnostics Market In 2030 - Segments Offering Most New Opportunities

40.3 Prostate Cancer Nuclear Medicine Diagnostics Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Overview Of Key Products - Product Examples

Table 2: Global Prostate Cancer Nuclear Medicine Diagnostics Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Supply Chain Analysis

Table 4: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Raw Material Providers

Table 5: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Resource Providers

Table 6: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Manufacturers (Suppliers)

Table 7: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Distributors And Channel Partners

Table 8: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Key Technologies & Future Trends

Table 9: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Trends

Table 10: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major End Users

Table 11: Global Prostate Cancer Nuclear Medicine Diagnostics Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Prostate Cancer Nuclear Medicine Diagnostics Market - TAM, US$ Billion, 2025

Table 15: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Single Photon Emission Computed Tomography (SPECT), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Positron Emission Tomography (PET), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Taiwan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: Taiwan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Taiwan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South East Asia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: South East Asia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: South East Asia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Global Prostate Cancer Nuclear Medicine Diagnostics Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 95: Global Prostate Cancer Nuclear Medicine Diagnostics Market - Company Scoring Matrix

Table 96: Cardinal Health Financial Performance

Table 97: Bayer AG Financial Performance

Table 98: Novartis AG Financial Performance

Table 99: Siemens Healthineers AG Financial Performance

Table 100: GE Healthcare Financial Performance

Table 101: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Competitive Benchmarking (In USD Billions)

Table 102: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Competitive Dashboard

Table 103: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 104: Global, Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030

Table 105: Global, Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), Segmentation By Test Type, 2025 – 2030

Table 106: Global, Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

List Of Figures

Figure 1: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Overview Of Key Products - Product Examples

Figure 2: Global Prostate Cancer Nuclear Medicine Diagnostics Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Supply Chain Analysis

Figure 4: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Raw Material Providers

Figure 5: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Resource Providers

Figure 6: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Manufacturers (Suppliers)

Figure 7: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Distributors And Channel Partners

Figure 8: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Key Technologies & Future Trends

Figure 9: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major Trends

Figure 10: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Major End Users

Figure 11: Global Prostate Cancer Nuclear Medicine Diagnostics Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Prostate Cancer Nuclear Medicine Diagnostics Market - TAM, US$ Billion, 2025

Figure 15: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Single Photon Emission Computed Tomography (SPECT), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation Of Positron Emission Tomography (PET), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Taiwan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: Taiwan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Taiwan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South East Asia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: South East Asia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: South East Asia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Global Prostate Cancer Nuclear Medicine Diagnostics Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 95: Global Prostate Cancer Nuclear Medicine Diagnostics Market - Company Scoring Matrix

Figure 96: Cardinal Health Financial Performance

Figure 97: Bayer AG Financial Performance

Figure 98: Novartis AG Financial Performance

Figure 99: Siemens Healthineers AG Financial Performance

Figure 100: GE Healthcare Financial Performance

Figure 101: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Competitive Benchmarking (In USD Billions)

Figure 102: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Competitive Dashboard

Figure 103: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 104: Global, Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030

Figure 105: Global, Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), Segmentation By Test Type, 2025 – 2030

Figure 106: Global, Prostate Cancer Nuclear Medicine Diagnostics Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

Top Trends Driving Innovation and Change in the Healthcare Compliance Software Market: Technological Advancements In Healthcare Compliance Software

Global Healthcare Data Annotation Tools Market Projected to Reach $0.85 Billion by 2029 at a CAGR of 28.3%

Key Developments and Trends Steering the Healthcare Data Integration Market Forward: Innovative Healthcare Data Integration Solutions Revolutionize Clinical Trials

Major Trends and Emerging Patterns in the Healthcare Data Interoperability Market: Innovative Solutions Driving Healthcare Data Interoperability

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

3D Display Market Report 2026 - Global Outlook – By Product ( Volumetric, Stereoscopic), By Technology ( Digital Light Processing, Organic Light-Emitting Diode), By Access Methods ( Conventional or Screen-based Display, ...

Drugs For Benign Prostatic hypertrophy Market Report 2026 - Global Outlook – By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types ), By Distribution Channel (Hospital Pharmacies...

Equipment Finance Service Market Report 2026 - Global Outlook – By Type (Equipment Loan, Equipment Lease, Other Types), By Provider (Banks, Non-Banking Financial Company (NBFC), Other Providers), By Application (Transpor...

Blood Plasma Derivatives Market Report 2026 - Global Outlook – By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Other Types), By Application (Hemophilia, Hypogammaglobulinemia, Immunodefici...

Note Sorter Market Report 2026 - Global Outlook – By Sorter Type (Small-Sized Note Sorter, Medium-Sized Note Sorter, Large-Sized Note Sorter), By Enterprise Size (Large Enterprises, Small And Medium Enterprises ), By End...

Prostate Cancer Drugs Market Report 2026 - Global Outlook – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer ), By Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy ),...

Cancer Diagnostics Market Report 2026 - Global Outlook – By Products (Companion Diagnostics, Molecular Diagnostics), By Method (Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging), By Application (Cervical Cancer, Breast ...

Frequently Asked Questions

How big is the Prostate Cancer Nuclear Medicine Diagnostics Market?

The Prostate Cancer Nuclear Medicine Diagnostics market was valued at $0.99 billion in 2025, increased to $1.13 billion in 2026, and is projected to reach $1.84 billion by 2030.

What is the Prostate Cancer Nuclear Medicine Diagnostics market growth?

The global Prostate Cancer Nuclear Medicine Diagnostics market is expected to grow at a CAGR of 13.0% from 2026 to 2035 to reach $1.84 billion by 2035.

Who are the key players in Prostate Cancer Nuclear Medicine Diagnostics market?

Some Key Players in the Prostate Cancer Nuclear Medicine Diagnostics market Include, Cardinal Health, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, Curium Pharma, Telix Pharmaceuticals Ltd, Eckert And Ziegler AG, Point Bioph

Major trend in this market includes: Targeted Alpha-Particle Radiotherapy Advances Precision Treatment for Prostate Cancer . For further insights on this market. request a sample here

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2025. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Easte

Book your 30 minutes free consultation with our research experts

Contact Us